NASDAQ:ONCSOncoSec Medical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OncoSec Medical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.22 -0.01 (-0.45 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$2.10Now: $2.22▼$2.2850-Day Range$1.48MA: $1.83▼$2.4952-Week Range$1.04Now: $2.22▼$3.01Volume275,700 shsAverage Volume238,173 shsMarket Capitalization$50.51 millionP/E RatioN/ADividend YieldN/ABeta2.14 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (PISCES/KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (OMS-141/KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company has completed Phase I neoadjuvant clinical trial of ImmunoPulse IL-12 in combination with an anti-PD-1 in surgically resectable melanoma. Additionally, it is developing new DNA-encoded therapeutic candidates and tumor indications. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the PISCES/KEYNOTE-695 and OMS-141/KEYNOTE-890 studies; a collaboration with the GOG Foundation, Inc. to conduct a registration-enabled study of tavokinogene telseplasmid in women with recurrent/persistent cervical cancer; and a collaborative research agreement with Duke University School of Medicine in HER2+ breast cancer. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOncoSec Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, OncoSec Medical has a potential upside of 170.3% from its current price of $2.22.Amount of Analyst CoverageOncoSec Medical has received no research coverage in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesOncoSec Medical has received 299 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOncoSec Medical has received 397 “underperform” votes. (Add your “underperform” vote.)Community SentimentOncoSec Medical has received 57.04% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote “Outperform” if you believe ONCS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOncoSec Medical does not currently pay a dividend.Dividend GrowthOncoSec Medical does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoSec Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,504.00 in company stock.Percentage Held by InsidersOnly 0.71% of the stock of OncoSec Medical is held by insiders.Percentage Held by InstitutionsOnly 3.42% of the stock of OncoSec Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioOncoSec Medical has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.25 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCS Previous Symbol CUSIPN/A CIK1444307 Webwww.oncosec.com Phone855-662-6732Debt Debt-to-Equity Ratio1.93 Current Ratio1.16 Quick Ratio1.16Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book0.97Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-30,280,000.00 Net MarginsN/A Return on Equity-236.39% Return on Assets-151.23%Miscellaneous Employees33 Outstanding Shares22,752,000Market Cap$50.51 million Next Earnings Date6/12/2020 (Estimated) OptionableNot Optionable NASDAQ:ONCS Rates by TradingView Receive ONCS News and Ratings via Email Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter. OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions How has OncoSec Medical's stock been impacted by COVID-19 (Coronavirus)? OncoSec Medical's stock was trading at $1.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ONCS shares have increased by 62.0% and is now trading at $2.22. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of OncoSec Medical? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OncoSec Medical. When is OncoSec Medical's next earnings date? OncoSec Medical is scheduled to release its next quarterly earnings announcement on Friday, June 12th 2020. View our earnings forecast for OncoSec Medical. How were OncoSec Medical's earnings last quarter? OncoSec Medical Inc (NASDAQ:ONCS) posted its quarterly earnings results on Wednesday, October, 25th. The biotechnology company reported ($2.80) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.30) by $0.50. View OncoSec Medical's earnings history. When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work? OncoSec Medical's stock reverse split on Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for ONCS? 1 Wall Street analysts have issued 12 month price objectives for OncoSec Medical's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate OncoSec Medical's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 170.3% from the stock's current price. View analysts' price targets for OncoSec Medical. What are Wall Street analysts saying about OncoSec Medical stock? Here are some recent quotes from research analysts about OncoSec Medical stock: 1. According to Zacks Investment Research, "OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in San Diego, California. " (12/31/2019) 2. Maxim Group analysts commented, "OncoSec announced a collaboration agreement with Dana-Farber Cancer Institute whereby OncoSec acquired an exclusive option to licensing rights to CAR-T candidates and associated IP from research being conducted the Marasco Laboratory." (6/28/2019) Has OncoSec Medical been receiving favorable news coverage? Media stories about ONCS stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OncoSec Medical earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutOncoSec Medical. Are investors shorting OncoSec Medical? OncoSec Medical saw a increase in short interest in May. As of May 15th, there was short interest totaling 220,200 shares, an increase of 16.9% from the April 30th total of 188,300 shares. Based on an average trading volume of 248,000 shares, the days-to-cover ratio is presently 0.9 days. Approximately 2.5% of the shares of the stock are short sold. View OncoSec Medical's Current Options Chain. Who are some of OncoSec Medical's key competitors? Some companies that are related to OncoSec Medical include IVERIC bio (ISEE), Kalvista Pharmaceuticals (KALV), Paratek Pharmaceuticals (PRTK), Chimerix (CMRX), Five Prime Therapeutics (FPRX), Xeris Pharmaceuticals (XERS), Cerecor (CERC), vTv Therapeutics (VTVT), Avenue Therapeutics (ATXI), Nature's Sunshine Products (NATR), Strongbridge Biopharma (SBBP), Kindred Biosciences (KIN), Tyme Technologies (TYME), TAIWAN LIPOSOME/S (TLC) and Kezar Life Sciences (KZR). View all competitors. What other stocks do shareholders of OncoSec Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), XOMA (XOMA), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Walt Disney (DIS), Amarin (AMRN), Idera Pharmaceuticals (IDRA), Protalix Biotherapeutics (PLX), Rexahn Pharmaceuticals (REXN) and Arena Pharmaceuticals (ARNA). Who are OncoSec Medical's key executives? OncoSec Medical's management team includes the following people: Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 55)Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 39)Ms. Sara M. Bonstein, CFO, COO & Company Sec. (Age 38)Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer What is OncoSec Medical's stock symbol? OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS." Who are OncoSec Medical's major shareholders? OncoSec Medical's stock is owned by many different institutional and retail investors. Top institutional investors include Sigma Planning Corp (0.12%). Company insiders that own OncoSec Medical stock include Alpha Holdings, Inc, Avtar S Dhillon, Daniel J O'connor, James M Demesa, Punit Dhillon, Richard B Slansky and Sara Bonstein. View institutional ownership trends for OncoSec Medical. Which institutional investors are buying OncoSec Medical stock? ONCS stock was acquired by a variety of institutional investors in the last quarter, including Sigma Planning Corp. Company insiders that have bought OncoSec Medical stock in the last two years include Alpha Holdings, Inc, Daniel J O'connor, and James M Demesa. View insider buying and selling activity for OncoSec Medical. How do I buy shares of OncoSec Medical? Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is OncoSec Medical's stock price today? One share of ONCS stock can currently be purchased for approximately $2.22. How big of a company is OncoSec Medical? OncoSec Medical has a market capitalization of $50.51 million. OncoSec Medical employs 33 workers across the globe. What is OncoSec Medical's official website? The official website for OncoSec Medical is www.oncosec.com. How can I contact OncoSec Medical? OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
